|
|||||
|
|
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age,and race/ethnicity |
|
| Authors: | R. T. Chlebowski R. Haque H. Hedlin N. Col E. Paskett J. E. Manson J. T. Kubo K. C. Johnson J. Wactawski-Wende K. Pan G. Anderson |
| Affiliation: | 1. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA 2. Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, CA, USA 3. Department of Medicine, Stanford Prevention Research Center, Stanford University, Stanford, CA, USA 4. School of Osteopathic Medicine, University of New England, Biddeford, ME, USA 5. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA 6. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 7. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA 8. Department of Social and Preventive Medicine, State University of New York, Buffalo, NY, USA 9. Harbor-UCLA Medical Center, Torrance, CA, USA 10. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |